U.S. Markets closed

Cempra, Inc. (CEMP)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.850.00 (0.00%)
At close: 4:00PM EDT
People also watch
TTPHESPRCLVSFOLDPTCT
  • Its like buying JAZZ at $1 a few years ago now trading at $151
    (AXSM) Market Cap $90 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)
    Price:$3.90

    Shares Out: 23.5 Million

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
  • Buy-Out News Coming...

    MS has a buyer...

    GL

    A1
  • Sell Rating Just Came Out---Smart Consensus...

    GL

    A1
  • My guess is that CEMP is due for a pullback in the short-run. Ive been struggling with this stock lately. Some of my other trades have been from awesom-eSTOCKS which are working out pretty well.
  • Interesting comments by the new FDA Commissioner. Hopefully this opens a door for CEMP
    http://www.firstwordpharma.com/node/1472337#axzz4hL87UoLO

  • I would think if the merits of solithera were so high and the need for new antibiotics so strong that it would take only a mediocre management team to bring it to market
  • The happiness of your life depends on the quality of your thoughts.http://dataunion.tistory.com/10880

    Cempra Inc NASDAQ : CEMP Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.6 In other words, the correlation coefficient of the other stoc
    dataunion.tistory.com
  • wait til gottllieb mentions solithromycin
  • Below cash Value Now...

    Load all you can down here...

    GLTA

    A1
  • remembering that solithera did pass adcom, albeit narrowly, the FDA sent CEMP to the end of the line. leading me to believe that the little guy doesn't stand a chance
  • If you back out the cash the company is valued at 10MM - I thought this was a mistake so I checked multiple sources ha...nonetheless, I'm going to loading up on this!
  • PRTK 23
    AKAO 24
    TTPH 8
    CEMP 4
    Unbelievable that CEMP is at 4, compared with these other companies.
  • Maybe it would be good strategy to publicly announce that the company intends to request the new FDA chief re-evaluate soli's suitability for immediate marketing. This would give a Cemp a chance at reprieve and the new chief a chance to demonstrate his philosophy coming out the gate.
  • We have a new FDA Commissioner starting today.Cempra gets a reprieve with implementation of 21st Century Cures Act.
  • Something BIG is brewing. I did a tarot card reading.... ;-)
  • I used to be in but got out after 1st of year.Does anyone know if the lead researcher dr/old ceo is still around for support to the company.I cant remember her name.
  • up%100000 today
  • Buy-Out Coming!!!

    GL

    A1
  • Very Interesting.
    Here's what I'm thinking:::
    CEMP's president resigns today. Is that to clear the deck for a buyout? Possibly.
    CEMP has $200million in cash. That's more than the value of the stock at this price. Does that make CEMP a very attractive buyout candidate? Uh huh.
    CEMP has 2 late stage drugs with blockbuster potential if they can refigure the dosage to lower the hepatoxity in Sola...and bring Taksta to market.
    CEMP has been beaten down and technically is looking to explode. Just needs some positive fundamentals. Might happen today. Might happen in 2 months.
    Either way...I anticipate at least a 50% return.....soon!
  • Cempra has asked FDA for approval with post market studies.New FDA Commishioner Gottlieb ,implementing 21st Century Cures Act ,will approve Soli.